Research Summary

The long-term goal of the Mattis Lab is to understand molecular mechanisms in medical liver diseases especially non-alcoholic fatty liver disease. To better understand liver diseases, the laboratory is using patient fibroblast cell lines, reprogrammed to induced pluripotent stem cells (iPSCs) and differentiating these to liver cells including hepatocytes, cholangiocytes, and experimentally to other cellular lineages. Cell culture experiments underway in the Mattis lab focus on identifying unique pathways in these diseases that drive mechanisms of disease. Our lab has other small projects including cholangiocarcinoma and hepatocellular carcinoma deep sequencing and analysis.

Research Funding

  • June 1, 2023 - May 30, 2028 - Establishing patient-derived iPSCs as a platform for discovery research in NAFLD , MPI . Sponsor: NIDDK, Sponsor Award ID: RC2DK136052
  • June 8, 2021 - March 31, 2025 - Genetic Regulation of Nonalcoholic Fatty Liver Disease , MPI . Sponsor: NIH, Sponsor Award ID: R01DK130391
  • September 1, 2013 - July 31, 2019 - Regulation of Lipid Metabolism by miR-29a within Hepatocytes , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08DK098270


  • University of California, Berkeley, B.A., 1998, Molecular and Cell Biology
  • University of Illinois, Chicago, M.D., 2007, Medicine
  • University of Illinois, Urbana-Champaign, Ph.D., 2007, Biochemistry
  • University of California, San Francisco, 2009, Resident, Anatomic Pathology
  • University of California, San Francisco, 2009, Fellow, Surgical Pathology
  • University of California, San Francisco, 2010, Fellow, Liver/GI Pathology
  • University of California, San Francisco, 2014, Postdoctoral Fellow
  • California Institute for Regenerative Medicine, 2013, CIRM Clinical Fellow

Honors & Awards

  • 1998
    Biochemistry Trust Start-up Award, University of Illinois, Urbana-Champaign 
  • 1998-99
    Lycan Teaching Scholarship, University of Illinois, Urbana-Champaign 
  • 2007
    Alpha Omega Alpha Honor Medical Society, University of Illinois, Chicago 
  • 2010-13
    California Institute for Regenerative Medicine, Training Grant Award 
  • 2016
    UCSF Department of Pathology Start-up Award, San Francisco, California 

Selected Publications

  1. Sbierski-Kind J, Cautivo KM, Wagner JC, Dahlgren MW, Nilsson J, Krasilnikov M, Mroz NM, Lizama CO, Gan AL, Matatia PR, Taruselli MT, Chang AA, Caryotakis S, O'Leary CE, Kotas M, Mattis AN, Peng T, Locksley RM, Molofsky AB. Group 2 innate lymphoid cells constrain type 3/17 lymphocytes in shared stromal niches to restrict liver fibrosis. bioRxiv. 2023 Apr 28.  View on PubMed
  2. Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data. PLoS One. 2023; 18(4):e0271354.  View on PubMed
  3. Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT. DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia. Histopathology. 2023 Jul; 83(1):116-125.  View on PubMed
  4. Weng Y, Han S, Sekyi MT, Su T, Mattis AN, Chang TT. Self-Assembled Matrigel-Free iPSC-Derived Liver Organoids Demonstrate Wide-Ranging Highly Differentiated Liver Functions. Stem Cells. 2023 03 02; 41(2):126-139.  View on PubMed
  5. Akanuma N, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT. Fundic Gland Polyps Lack DNA Content Abnormality Characteristic of Other Adenomatous Precursor Lesions in the Gastrointestinal Tract. Mod Pathol. 2023 05; 36(5):100117.  View on PubMed
  6. Pierce GF, Mattis AN. Transient expression of factor VIII and achronic high-fat diet induces ER stress and late hepatocyte oncogenesis. Mol Ther. 2022 Nov 23.  View on PubMed
  7. Yu A, Cable C, Sharma S, Shihan MH, Mattis AN, Mileva I, Hannun YA, Duwaerts CC, Chen JY. Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis. Front Med (Lausanne). 2022; 9:881848.  View on PubMed
  8. Muñoz A, Theusch E, Kuang YL, Nalula G, Peaslee C, Dorlhiac G, Landry MP, Streets A, Krauss RM, Iribarren C, Mattis AN, Medina MW. Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol. 2022; 14(5):1174-1176.e6.  View on PubMed
  9. Bogliotti Y, Vander Roest M, Mattis AN, Gish RG, Peltz G, Anwyl R, Kivlighn S, Schuur ER. Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review. Cells. 2022 06 22; 11(13).  View on PubMed
  10. Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S, Russell CB, Kim B, Lawal A, Rangarajan S, Lester W, Bunting S, Pierce GF, Pasi KJ, Wong WY. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med. 2022 04; 28(4):789-797.  View on PubMed
  11. Mohammed N, Rabinovitch PS, Wang D, Kovári BP, Mattis AN, Lauwers GY, Choi WT. Nonampullary Duodenal Adenomas in Familial Adenomatous Polyposis and Sporadic Patients Lack the DNA Content Abnormality That Is Characteristic of the Adenoma-Carcinoma Sequence Involved in the Development of Other Gastrointestinal Malignancies. Am J Surg Pathol. 2021 12 01; 45(12):1694-1702.  View on PubMed
  12. Peaslee C, Esteva-Font C, Su T, Munoz-Howell A, Duwaerts CC, Liu Z, Rao S, Liu K, Medina M, Sneddon JB, Maher JJ, Mattis AN. Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation. Hepatology. 2021 10; 74(4):2102-2117.  View on PubMed
  13. Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT. Gastric Intestinal Metaplasia in Mucosa Adjacent to Gastric Cancers Is Rarely Associated With the Aneuploidy That Is Characteristic of Gastric Dysplasia or Cancer. Am J Surg Pathol. 2021 10 01; 45(10):1374-1381.  View on PubMed
  14. Bowman CJ, Zhang R, Balitzer D, Wang D, Rabinovitch PS, Kovári BP, Mattis AN, Kakar S, Lauwers GY, Choi WT. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue. Mod Pathol. 2021 10; 34(10):1889-1900.  View on PubMed
  15. Duwaerts CC, Le Guillou D, Her CL, Phillips NJ, Willenbring H, Mattis AN, Maher JJ. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile. Gastroenterology. 2021 06; 160(7):2591-2594.e6.  View on PubMed
  16. Lee H, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT. Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia. Histopathology. 2021 May; 78(6):814-830.  View on PubMed
  17. Duwaerts CC, Siao K, Soon RK, Her C, Iwawaki T, Kohno K, Mattis AN, Maher JJ. Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1α. Cell Death Differ. 2021 05; 28(5):1455-1465.  View on PubMed
  18. Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, Ferreira DDS, Ma HY, Duwaerts CC, Espanol-Suner R, Wei L, Newcomb B, Mileva I, Canals D, Hannun YA, Chung RT, Mattis AN, Fuchs BC, Tager AM, Yimlamai D, Weaver VM, Mullen AC, Sheppard D, Chen JY. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Sci Transl Med. 2020 08 19; 12(557).  View on PubMed
  19. Alkhani A, Levy CS, Tsui M, Rosenberg KA, Polovina K, Mattis AN, Mack M, Van Dyken S, Wang BM, Maher JJ, Nijagal A. Ly6cLo non-classical monocytes promote resolution of rhesus rotavirus-mediated perinatal hepatic inflammation. Sci Rep. 2020 04 28; 10(1):7165.  View on PubMed
  20. Wen KW, Rabinovitch PS, Wang D, Mattis AN, Ferrell LD, Choi WT. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions. Virchows Arch. 2020 Oct; 477(4):527-534.  View on PubMed

Go to UCSF Profiles, powered by CTSI